Dr. John Charles Leighton Jr., MD

Dr. Leighton practices at Jefferson Einstein Philadelphia Hospital in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Leighton's NPI, 1861461162, was assigned on March 17, 2006. Dr. Leighton graduated from Temple University School of Medicine in 1989. Dr. Leighton holds Pennsylvania license MD045885L.

Dr. Leighton's primary practice is Jefferson Einstein Philadelphia Hospital, at 5501 Old York Road, Philadelphia, PA 19141 in Philadelphia County. The practice phone is (215) 456-6090.

Dr. Leighton's primary practice is Jefferson Einstein Philadelphia Hospital in Philadelphia, Pennsylvania, part of Thomas Jefferson University. The medical group on file is Einstein Gastroenterology Associates. Dmand AI also links Dr. Leighton to 1 more dialysis center, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leighton practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Leighton's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Leighton is licensed in Pennsylvania.

CMS data shows 706 Medicare services from Dr. Leighton across 10 procedure codes in 2024, for 213 Medicare patients. Medicare paid $60,598 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 213 Medicare patients who saw Dr. Leighton in 2024. The largest group is 65 to 74, with 99 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 33% are also on Medicaid. Their average risk score is 2.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leighton's median patient age at 66, with 54% women.

In 2024, Dr. Leighton wrote 1,064 Medicare Part D claims for 186 patients. 74% of them were for generic drugs. CMS names the drug for 835 of them, across 25 drugs with 11 or more claims each, at $1,857,439 in total drug cost. In 2023, CMS named 801 claims across 28 drugs.

Dr. Leighton accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leighton as offering telehealth.

Dmand AI links 11 papers to Dr. Leighton, published from 2011 to 2020. 2013 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Colorectal Neoplasms and Antibodies, Monoclonal, Humanized. Dr. Leighton has published most often in Cancer. Dr. Leighton's most frequent co-authors are William J. Tester, MD, Claudia Mattos Da Costa Dourado, MD and Rashmika Rushikesh Potdar, MD.

Dmand AI links Dr. Leighton to 4 clinical trials, 2 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Carcinoma, Hepatocellular. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 42 general payments to Dr. Leighton from 24 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 59% of the total. AstraZeneca Pharmaceuticals LP paid the most, $573.

Dr. Leighton graduated from Temple University School of Medicine in 1989.